Experimental vaccine aims to boost immune attack on colorectal cancer
NCT ID NCT06011772
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 41 times
Summary
This early-phase trial tests whether adding the CIMAvax-EGF vaccine to standard chemotherapy and targeted drugs can trigger an immune response against metastatic colorectal cancer. Only 2 participants with a specific gene type (RAS/BRAF wild-type) were enrolled. The main goal is to see if the vaccine produces enough antibodies, with progression-free survival also tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CIMAvax-EGF vaccine (a vaccine that targets epidermal growth factor)
What this could lead to
If it works, this could point toward a new way to boost the immune system against colorectal cancer when combined with standard treatments.
What could go wrong
This is a very early phase 0 trial with only 2 participants, so results are preliminary and may not apply to others. The vaccine may not trigger a strong enough immune response.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.